Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • 1107 Immune cell heterogeneity...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Export Ready — 
1107 Immune cell heterogeneity in lupus nephritis kidneys and its relation to histopathological features: lessons from the accelerating medicines partnership (AMP) in SLE Consortium

1107 Immune cell heterogeneity in lupus nephritis kidneys and its relation to histopathological features: lessons from the accelerating medicines partnership (AMP) in SLE Consortium

Bibliographic Details
Main Authors: Richard Furie, Joel M Guthridge, Judith A James, Maria Dall’Era, Michelle A Petri, Chaim Putterman, Jill P Buyon, Diane L Kamen, Betty Diamond, David Wofsy, Soumya Raychaudhuri, Thomas Tuschl, Jennifer Grossman, Peter M Izmirly, Qian Xiao, Nir Hacohen, Kenneth C Kalunian, Michael B Brenner, Mariko Ishimori, H Michael Belmont, Robert Clancy, ANNE DAVIDSON, Matthias Kretzler, Michael Weisman, Celine C Berthier, Andrea Fava, Jennifer L Barnas, Jennifer H Anolik, Paul J Hoover, Deepak A Rao, Arnon Arazi, William Apruzzese, Fernanda Payan-Schober, Saori Sakaue, James Lederer, Michael Peters, Tony Jones, Jospeh Mears, Thomas M Eisenhaure, Siddarth Gurajala, Derek Fine, David A Hildeman, Steve Woodle, Maureen A McMahon, Jeffery Hodgin
Format: Article
Language:English
Published: BMJ Publishing Group 2022-12-01
Series:Lupus Science and Medicine
  • Holdings
  • Description
  • Similar Items
  • Staff View

Similar Items

  • 1009 In-depth analysis of myeloid cell subsets in lupus nephritis kidneys provides insights into disease mechanisms: lessons from the accelerating medicines partnership (AMP) in RA/SLE consortium
    by: Richard Furie, et al.
    Published: (2024-05-01)
  • Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: data from the Accelerating Medicines Partnership Lupus Network
    by: Peter M. Izmirly, et al.
    Published: (2024-02-01)
  • LO-006 Change in urinary biomarkers at three months predicts 1-year treatment response of lupus nephritis better than proteinuria
    by: Richard Furie, et al.
    Published: (2023-07-01)
  • 1012 Deep peripheral blood immunophenotyping identifies a subgroup of lupus nephritis patients characterized by high type 1 interferon signaling, persistent activated immune cells and poor renal response to standard of care at 1 year
    by: Richard Furie, et al.
    Published: (2024-05-01)
  • 1702 Patients enrolled in the accelerating medicines partnership (AMP) RA/SLE network with isolated renal disease report minimal quality of life impairment on PROMIS-29 compared to patients with extrarenal symptoms
    by: Richard Furie, et al.
    Published: (2022-12-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs